VCM
AST

Versant Capital Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Versant Capital Management’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-52
Closed – – 1866
2018
Q4 		$0 Hold
52
– – ﹤0.01% 1781
2018
Q3 		$0 Hold
52
– – ﹤0.01% 1753
2018
Q2 		$0 Hold
52
– – ﹤0.01% 1744
2018
Q1 		$0 Hold
52
– – ﹤0.01% 1783
2017
Q4 		$0 Hold
52
– – ﹤0.01% 1734
2017
Q3 		$0 Hold
52
– – ﹤0.01% 1669
2017
Q2 		$0 Hold
52
– – ﹤0.01% 1632
2017
Q1 		$0 Hold
52
– – ﹤0.01% 1627
2016
Q4 		$0 Hold
52
– – ﹤0.01% 1634
2016
Q3 		$0 Hold
52
– – ﹤0.01% 1582
2016
Q2 		$0 Hold
52
– – ﹤0.01% 1530
2016
Q1 		$0 Hold
52
– – ﹤0.01% 1550
2015
Q4 		$0 Buy
+52
New +$240 ﹤0.01% 1492

Versant Capital Management's AST Position: Q1 2019 in Review

Versant Capital Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 52 shares.

Versant Capital Management first reported a position in AST in Q4 2015 and held it in 13 quarters. The position peaked at $0 in Q4 2018. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.

  • Versant Capital Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
  • Versant Capital Management sold 52 Asterias Biotherapeutics Inc. Series A shares in Q1 2019.
  • Versant Capital Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2015 and held it in 13 quarters.
  • Versant Capital Management's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q4 2018.
  • 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.

Based on Versant Capital Management's 13F filing for Q1 2019, filed 23 Apr 2019.